BREXAFEMME- ibrexafungerp tablet, film coated
SCYNEXIS, INC.
----------
MEDICATION GUIDE
BREXAFEMME® [brex a fem] (ibrexafungerp tablets) for oral use |
What is the most important information I should know about BREXAFEMME?
BREXAFEMME may cause serious side effects, including:
See “Do not take BREXAFEMME if you:” |
What is BREXAFEMME?
|
Do not take BREXAFEMME if you:
|
Before you take BREXAFEMME, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. |
How should I take BREXAFEMME?
|
What are the possible side effects of BREXAFEMME?
These are not all the possible side effects of BREXAFEMME. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store BREXAFEMME?
|
General information about the safe and effective use of BREXAFEMME.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BREXAFEMME for a condition for which it was not prescribed. Do not give BREXAFEMME to other people even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BREXAFEMME that is written for health professionals. |
What are the ingredients in BREXAFEMME?
Active ingredient: ibrexafungerp Inactive ingredients: Tablet core: butylated hydroxyanisole, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, and microcrystalline cellulose. Tablet film coating: FD&C Blue #2, FD&C Red #40, hydroxypropyl cellulose, hydroxypropylmethyl cellulose 2910, talc and titanium dioxide. BREXAFEMME is a registered trademark of SCYNEXIS, Inc. Manufactured for: SCYNEXIS, Inc., Jersey City, New Jersey, 07302 ©2022 SCYNEXIS, Inc. For more information, call 1-888-982-SCYX (7299) or go to www.brexafemme.com |
This Medication Guide -has been approved by the U.S. Food and Drug Administration Revised: 11/2022